A practical guide to the evaluation and treatment of male lower urinary tract symptoms in the primary care setting

Aims:  Lower urinary tract symptoms (LUTS) are common in both men and women, and are among the most prevalent patient complaints heard by primary care physicians (PCPs). This article aims to provide PCPs with a logical algorithm for the assessment and initiation of treatment for LUTS in the male patient.

[1]  C. Roehrborn,et al.  Benign prostatic hyperplasia. , 2020, BMJ.

[2]  W. Willett,et al.  Fruit and vegetable consumption, intake of micronutrients, and benign prostatic hyperplasia in US men. , 2007, The American journal of clinical nutrition.

[3]  M. Emberton,et al.  The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta‐analysis , 2007, BJU international.

[4]  M. Naslund,et al.  Managing enlarged prostate in primary care , 2006, International journal of clinical practice.

[5]  M. T. Rosenberg.  The sad, misunderstood prostate: understanding perceptions and reality , 2006, International journal of clinical practice.

[6]  S. Kaplan,et al.  Public, patient, and professional attitudes towards the diagnosis and treatment of enlarged prostate: a landmark national US survey * , 2006, International journal of clinical practice.

[7]  A. Te,et al.  Overactive bladder in the male patient: Epidemiology, etiology, evaluation, and treatment , 2006, Current urology reports.

[8]  J. Nickel.  BPH: costs and treatment outcomes. , 2006, The American journal of managed care.

[9]  S. Kaplan,et al.  Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. , 2006, The Journal of urology.

[10]  S. Kaplan,et al.  Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. , 2005, The Journal of urology.

[11]  C. Chapple,et al.  A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. , 2005, European urology.

[12]  C. Moser,et al.  Früchte und Gemüse , 2005 .

[13]  John T. Wei,et al.  Urologic diseases in America project: benign prostatic hyperplasia. , 2005, The Journal of urology.

[14]  W. Steers,et al.  An investigation of dose titration with darifenacin, an M3‐selective receptor antagonist , 2005, BJU international.

[15]  R. Roberts,et al.  Prevalence of conditions potentially associated with lower urinary tract symptoms in men , 2005, BJU international.

[16]  L. Cardozo,et al.  The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects , 2005, BJU international.

[17]  F. Lowe.  Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. , 2004, Clinical therapeutics.

[18]  J. Lee,et al.  Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder , 2004, BJU international.

[19]  P. Rochon,et al.  Management of overactive bladder , 2010, Nature Reviews Urology.

[20]  P. Abrams,et al.  Guideline for the primary care management of male lower urinary tract symptoms , 2004, BJU international.

[21]  K. Andersson.  Antimuscarinics for treatment of overactive bladder , 2004, The Lancet Neurology.

[22]  C. Roehrborn,et al.  The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. , 2003, The New England journal of medicine.

[23]  Seung-June Oh,et al.  Accuracy of bladder volume determinations by ultrasonography: are they accurate over entire bladder volume range? , 2003, Urology.

[24]  W. Stewart,et al.  Prevalence and burden of overactive bladder in the United States , 2003, World Journal of Urology.

[25]  H. V. van Melick,et al.  Correlations of urodynamic changes with changes in symptoms and well-being after transurethral resection of the prostate. , 2002, The Journal of urology.

[26]  W. Willett,et al.  Intakes of energy and macronutrients and the risk of benign prostatic hyperplasia. , 2002, The American journal of clinical nutrition.

[27]  Poul Jennum,et al.  The standardisation of terminology in nocturia: Report from the standardisation sub‐committee of the International Continence Society , 2002, Neurourology and urodynamics.

[28]  Magnus Fall,et al.  The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. , 2003, Urology.

[29]  A. Tubaro,et al.  A probability based system for combining simple office parameters as a predictor of bladder outflow obstruction. , 2001, The Journal of urology.

[30]  J. Blaivas,et al.  Detrusor instability in men: correlation of lower urinary tract symptoms with urodynamic findings. , 2001, The Journal of urology.

[31]  C. Roehrborn,et al.  Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: pooled analysis of eleven controlled studies with alfuzosin. , 2001, Urology.

[32]  McGhan Wf.  Cost effectiveness and quality of life considerations in the treatment of patients with overactive bladder. , 2001, The American journal of managed care.

[33]  N. Oakley.  Risk factors for lower urinary tract symptoms in elderly men. , 2000 .

[34]  P. Goode,et al.  Combined Behavioral and Drug Therapy for Urge Incontinence in Older Women , 2000, Journal of the American Geriatrics Society.

[35]  S. Madersbacher,et al.  Risk Factors for Lower Urinary Tract Symptoms in Elderly Men , 2000, European Urology.

[36]  M. Barry,et al.  The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. , 1998, The Journal of urology.

[37]  R. Kirby.  Terazosin in benign prostatic hyperplasia: effects on blood pressure in normotensive and hypertensive men. , 1998, British journal of urology.

[38]  R. Guthrie,et al.  Practice patterns among primary care physicians in benign prostatic hyperplasia and prostate cancer. , 1997, Family medicine.

[39]  S. Kaplan,et al.  Etiology of voiding dysfunction in men less than 50 years of age. , 1996, Urology.

[40]  R. Kirby.  Doxazosin in benign prostatic hyperplasia: effects on blood pressure and urinary flow in normotensive and hypertensive men. , 1995, Urology.

[41]  J. Oesterling,et al.  New diagnostic and treatment guidelines for benign prostatic hyperplasia. Potential impact in the United States. , 1995, Archives of internal medicine.

[42]  R. Millard,et al.  The accuracy of portable ultrasound scanning in the measurement of residual urine volume. , 1994, The Journal of urology.

[43]  M. Barry,et al.  The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. , 1992, The Journal of urology.

[44]  C. Eaton,et al.  Regulation of prostate growth. , 1991, The Journal of endocrinology.

[45]  P. Walsh,et al.  The development of human benign prostatic hyperplasia with age. , 1984, The Journal of urology.

[46]  P. Suter,et al.  of a on Fruit and Vegetable , 2019 .

[47]  M. Miner,et al.  Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function. , 2006, Clinical therapeutics.

[48]  S. Kaplan.  Update on the american urological association guidelines for the treatment of benign prostatic hyperplasia. , 2006, Reviews in urology.

[49]  R. Bruskewitz.  Quality of life and sexual function in patients with benign prostatic hyperplasia. , 2003, Reviews in urology.

[50]  W. Mcghan.  Cost effectiveness and quality of life considerations in the treatment of patients with overactive bladder. , 2001, The American journal of managed care.

[51]  D. Roth,et al.  Measurement of Postvoid Residual Urine with Portable Transabdominal Bladder Ultrasound Scanner and Urethral Catheterization , 2000, International Urogynecology Journal.

[52]  M. Lieber,et al.  Distribution of post-void residual urine volume in randomly selected men. , 1999, The Journal of urology.

[53]  G. Kobelt-Nguyen,et al.  Urge incontinence. Quality of life and patients' valuation of symptom reduction. , 1998, PharmacoEconomics.